The mitogen-activated protein kinase pathway plays a prominent role in the pathogenesis of low-grade serous carcinoma of the ovary, and provides an attractive target for novel therapeutic agents. This evidence concerns the gene WNK2 and ovarian serous adenocarcinoma.